MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
-7.84%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$375M
AUM Growth
+$375M
(-25%)
Cap. Flow
-$73.1M
Cap. Flow
% of AUM
-19.51%
Top 10 Holdings %
Top 10 Hldgs %
61.48%
Holding
38
New
4
Increased
8
Reduced
6
Closed
6
Top Buys
| 1 |
Olema Pharmaceuticals
OLMA
|
$17.2M |
| 2 |
Structure Therapeutics
GPCR
|
$11.6M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$9.11M |
| 4 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$4.58M |
| 5 |
Viking Therapeutics
VKTX
|
$3.6M |
Top Sells
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$445M
| $69.2M | 18.48% | 7,648,268 | – | – |
|
|
2
Olema Pharmaceuticals
OLMA
$375M
| $22.9M | 6.12% | 1,857,681 +1,395,181 | +302% | +$17.2M |
|
3
Geron
GERN
$893M
| $22.7M | 6.06% | 10,712,481 +1,521,191 | +17% | +$3.22M |
|
4
Repare Therapeutics
RPTX
$71.7M
| $19.8M | 5.29% | 1,639,849 | – | – |
|
5
iTeos Therapeutics
ITOS
| $19.1M | 5.1% | 1,745,943 | – | – |
|
6
Intellia Therapeutics
NTLA
$1.22B
| $17.2M | 4.6% | 544,639 | – | – |
|
7
MoonLake Immunotherapeutics
MLTX
$3.54B
| $16.8M | 4.48% | 294,190 -921 | -0.3% | -$52.5K |
|
8
Iovance Biotherapeutics
IOVA
$807M
| $15M | 3.99% | 3,287,397 +337,279 | +11% | +$1.53M |
|
9
Crinetics Pharmaceuticals
CRNX
$2.92B
| $14.2M | 3.8% | 479,053 | – | – |
|
10
Insmed
INSM
$28.8B
| $13.3M | 3.56% | 527,458 -2,285 | -0.4% | -$57.7K |
|
|
11
Structure Therapeutics
GPCR
$1.11B
| $11.6M | 3.11% | +230,761 | New | +$11.6M |
|
|
VERV
12
DELISTED
Verve Therapeutics
VERV
| $11.4M | 3.04% | 857,940 | – | – |
|
13
Relay Therapeutics
RLAY
$619M
| $11.4M | 3.04% | 1,352,133 -2,235 | -0.2% | -$18.8K |
|
14
Regenxbio
RGNX
$451M
| $10.8M | 2.89% | 656,718 | – | – |
|
|
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
| $9.11M | 2.43% | +610,770 | New | +$9.11M |
|
|
KRTX
16
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $9M | 2.4% | 53,210 -189 | -0.4% | -$32K |
|
17
Amicus Therapeutics
FOLD
$2.34B
| $8.71M | 2.32% | 716,139 +200,000 | +39% | +$2.43M |
|
18
Revolution Medicines
RVMD
$7.1B
| $7.57M | 2.02% | 273,408 | – | – |
|
19
Xeris Biopharma Holdings
XERS
$1.26B
| $7.42M | 1.98% | 3,987,967 +12,968 | +0.3% | +$24.1K |
|
|
AVDL
20
Avadel Pharmaceuticals
AVDL
$1.43B
| $6.84M | 1.83% | 664,224 +279,234 | +73% | +$2.88M |
|
21
Axsome Therapeutics
AXSM
$6.05B
| $6.54M | 1.75% | 93,586 | – | – |
|
22
Madrigal Pharmaceuticals
MDGL
$9.76B
| $5.97M | 1.59% | 40,859 +2,848 | +7% | +$416K |
|
23
KalVista Pharmaceuticals
KALV
$678M
| $5.57M | 1.49% | 577,958 -183,580 | -24% | -$1.77M |
|
24
Werewolf Therapeutics
HOWL
$59.9M
| $5.11M | 1.36% | 2,388,011 | – | – |
|
25
Travere Therapeutics
TVTX
$1.56B
| $4.94M | 1.32% | 552,846 | – | – |
|